Apixaban for Blood Clots in Cancer Patients
(STREAM-Line Trial)

Recruiting in Palo Alto (17 mi)

Overseen byTzu-Fei Wang, MD, MPH

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Recruiting

Sponsor: Ottawa Hospital Research Institute

Must be taking: Anticoagulants

Must not be taking: Strong enzyme inhibitors

Disqualifiers: Active bleeding, Atrial fibrillation, others

No Placebo Group

Prior Safety Data

Approved in 2 Jurisdictions

Trial Summary

What is the purpose of this trial?This trial seeks to evaluate a management strategy after the initial 3 months of standard therapeutic anticoagulation for patients with cancer and catheter-related upper extremity deep vein thrombosis (DVT).

Eligibility Criteria

This trial is for cancer patients who have had a catheter-related blood clot in an upper extremity and completed 3 months of standard blood thinner treatment. Specific eligibility details are not provided, so it's best to contact the study team for more information.

Inclusion Criteria

Able and willing to provide informed consent

I am an adult with cancer diagnosed or treated in the last 6 months, not in complete remission.

I have had a blood clot in my arm due to a catheter and have been on blood thinners for at least 3 months.

Exclusion Criteria

I am not on blood thinners at the time of joining the study.

Known contraindication for apixaban, such as allergy, hypersensitivity, or pregnancy

I do not have active bleeding or conditions that prevent blood thinning treatments.

+2 more

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Initial Treatment

Participants receive standard therapeutic anticoagulation for 3 months

12 weeks

STREAM-Line Management

Participants are managed with a prophylactic dose of apixaban as long as a central venous catheter or active cancer is present

Up to 6 months

Day 90±14 and Day 180+14 follow-up visits by phone call or in person

Follow-up

Participants are monitored for safety and effectiveness after treatment

6 months

Participant Groups

The trial is testing Apixaban as a secondary prevention strategy for deep vein thrombosis (DVT) after initial anticoagulation therapy in cancer patients with catheter-related DVT.

1Treatment groups

Experimental Treatment

Group I: ApixabanExperimental Treatment1 Intervention

2.5 mg twice daily

Apixaban is already approved in European Union, United States for the following indications:

🇪🇺 Approved in European Union as Eliquis for: